Targeting the Anti-Inflammatory Effects of High-Density Lipoprotein

American Journal of Cardiology

Volumn 100, Issue 11 SUPPL. 1, 2007, Pages

  Ansell, Benjamin J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; HIGH DENSITY LIPOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN;

ARTICLE; ATHEROSCLEROSIS; CELL ACTIVATION; CLINICAL ARTICLE; CONTROLLED STUDY; GLUCOSE BLOOD LEVEL; GLYCATION; HUMAN; INFLAMMATION; LIFESTYLE; MACROPHAGE; OXIDATION; PRIORITY JOURNAL;

ATHEROSCLEROSIS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; LIPOPROTEINS, HDL; OXIDATION-REDUCTION;

EID: 36448944299     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2007.08.006     Document Type: Article

References (36)

1. Ansell B.J., Fonarow G.C., and Fogelman A.M. High-density lipoprotein: is it always atheroprotective?. Curr Atheroscler Rep 8 (2006) 405-411
2. Navab M., Anantharamaiah G.M., Reddy S.T., Van Lenten B.J., Ansell B.J., Fonarow G.C., Vahabzadeh K., Hama S., Hough G., Kamranpour N., et al. The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. J Lipid Res 45 (2004) 993-1007
3. Cockerill G.W., Rye K.-A., Gamble J.R., Vadas M.A., and Barter P.J. High-density lipoproteins inhibit cytokine-induced expression of endothelial cell adhesion molecules. Arterioscler Thromb Vasc Biol 15 (1995) 1987-1994
4. Watson A., Berliner J., Hama S., La Du B.N., Faull K., Fogelman A., and Navab M. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 96 (1995) 2882-2891
5. Navab M., Anantharamaiah G.M., Reddy S.T., Van Lenten B.J., Ansell B.J., Hama S., Hough G., Bachini E., Grijalva V.R., Wagner A., Shaposhnik Z., and Fogelman A.M. The double jeopardy of HDL. Ann Med 37 (2005) 1-6
6. Ansell B.J., Watson K.E., Fogelman A.M., Navab M., and Fonarow G.C. High-density lipoprotein function: recent advances. J Am Coll Cardiol 46 (2005) 1792-1798
7. Fogelman A.M. When good cholesterol goes bad. Nat Med 10 (2004) 902-903
8. Fogelman A.M. When pouring water on the fire makes it burn brighter. Cell Metab 2 (2005) 6-8
9. Navab M., Imes S.S., Hama S.Y., Hough G.P., Ross L.A., Bork R.W., Valente A.J., Berliner J.A., Drinkwater D.C., Laks H., et al. Monocyte transmigration induced by modification of low density lipoprotein in cocultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein. J Clin Invest 88 (1991) 2039-2046
10. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., and Witztum J.L. Beyond cholesterol: modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320 (1989) 915-924
11. Nathan C.F. Secretory products of macrophages. J Clin Invest 79 (1987) 319-326
12. Navab M., Hama S.Y., Cooke C.J., Anantharamaiah G.M., Chaddha M., Jin L., Subbanagounder G., Faull K.F., Reddy S.T., Miller N.E., and Fogelman A.M. Normal high density lipoprotein inhibits three steps in the formation of mildly oxidized low density lipoprotein: step 1. J Lipid Res 41 (2000) 1481-1494
13. Miyazaki A., Rahim A.T., Ohta T., Morino Y., and Horiuchi S. High density lipoprotein mediates selective reduction in cholesteryl esters from macrophage foam cells. Biochim Biophys Acta 1126 (1992) 73-80
14. Gabay C., and Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 340 (1999) 448-454
15. Subbanagounder G., Leitinger N., Schwenke D.C., Wong J.W., Lee H., Rizza C., Watson A.D., Faull K.F., Fogelman A.M., and Berliner J.A. Determinants of bioactivity of oxidized phospholipids. Specific oxidized fatty acyl groups at the sn-2 position. Arterioscler Thromb Vasc Biol 20 (2000) 2248-2254
16. Navab M., Hama S.Y., Hough G.P., Subbanagounder G., Reddy S.T., and Fogelman A.M. A cell-free assay for detecting HDL that is dysfunctional in preventing the formation of or inactivating oxidized phospholipids. J Lipid Res 42 (2001) 1308-1317
17. Ansell B.J., Navab M., Hama S., Kamranpour N., Fonarow G., Hough G., Rahmani S., Mottahedeh R., Dave R., Reddy S.T., and Fogelman A.M. Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 108 (2003) 2751-2756
18. Gowri M.S., Van der Westhuyzen D.R., Bridges S.R., and Anderson J.W. Decreased protection by HDL from poorly controlled type 2 diabetic subjects against LDL oxidation may be due to the abnormal composition of HDL. Arterioscler Thromb Vasc Biol 19 (1999) 2226-2233
19. Hedrick C.C., Thorpe S.R., Fu M.X., Harper C.M., Yoo J., Kim S.M., Wong H., and Peters A.L. Glycation impairs high-density lipoprotein function. Diabetologia 43 (2000) 312-320
20. Ferretti G., Bacchetti T., Marchionni C., Caldarelli L., and Curatola G. Effect of glycation of high density lipoproteins on their physicochemical properties and on paraoxonase activity. Acta Diabetol 38 (2001) 163-169
21. Ferretti G., Bacchetti T., Negre-Salvayre A., Salvayre R., Dousset N., and Curatola G. Structural modifications of HDL and functional consequences. Atherosclerosis 184 (2006) 1
22. Van Lenten B.J., Hama S.Y., de Beer F.C., Stafforini D.M., McIntyre T.M., Prescott S.M., La Du B.N., Fogelman A.M., and Navab M. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response: loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 96 (1995) 2758-2767
23. Van Lenten B.J., Wagner A.C., Nayak D.P., Hama S., Navab M., and Fogelman A.M. High-density lipoprotein loses its anti-inflammatory properties during acute influenza A infection. Circulation 103 (2001) 2283-2288
24. Smeeth L., Thomas S.L., Hall A.J., Hubbard R., Farrington P., and Vallance P. Risk of myocardial infarction and stroke after acute infection or vaccination. N Engl J Med 351 (2004) 2611-2618
25. Manzi S., Meilahn E.N., Rairie J.E., Conte C.G., Medsger Jr. T.A., Jansen-McWilliams L., D'Agostino R.B., and Kuller L.H. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 145 (1997) 408-415
26. Maradit-Kremers H., Nicola P.J., Crowson C.S., Ballman K.V., and Gabriel S.E. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 52 (2005) 722-732
27. McMahon M., Grossman J., Fitzgerald J., Dahlin-Lee E., Wallace D.J., Thong B.Y., Badsha H., Kalunian K., Charles C., Navab M., Fogelman A.M., and Hahn B.H. Proinflammatory high-density lipoprotein as a biomarker for atherosclerosis in patients with systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 54 (2006) 2541-2549
28. Charles-Schoeman C., Khanna D., Furst D.E., McMahon M., Reddy S., Fogelman A.M., Paulus H.E., Park G.S., Gong T., and Ansell B.J. Effects of high-dose atorvastatin on HDL anti-inflammatory/pro-inflammatory function and disease activity in patients with rheumatoid arthritis: results of the Statin Anti-Rheumatic Activity (SARA) pilot study. J Rheumatol (2007) (in press)
29. Roberts C.K., Ng C., Hama S., Eliseo A.J., and Barnard R.J. Effect of a short-term diet and exercise intervention on inflammatory/anti-inflammatory properties of HDL in overweight/obese men with cardiovascular risk factors. J Appl Physiol 101 (2006) 1727-1732
30. Nicholls S.J., Lundman P., Harmer J.A., Cutri B., Griffiths K.A., Rye K.-A., Barter P.J., and Celermajer D.S. Consumption of saturated fat impairs the anti-inflammatory properties of high-density lipoproteins and endothelial function. J Am Coll Cardiol 48 (2006) 715-720
31. Tall A.R., Yvan-Charvet L., and Wang N. The failure of torcetrapib: was it the molecule or the mechanism?. Arterioscler Thromb Vasc Biol 27 (2007) 257-260
32. Barter P. The inflammation: lipoprotein cycle. Atheroscler Suppl 6 (2005) 15-20
33. Baker P.W., Rye K.A., Gamble J.R., Vadas M.A., and Barter P.J. Phospholipid composition of reconstituted high density lipoproteins influences their ability to inhibit endothelial cell adhesion molecule expression. J Lipid Res 41 (2000) 1261-1267
34. Rohrer L., Hersberger M., and von Eckardstein A. High density lipoproteins in the intersection of diabetes mellitus, inflammation and cardiovascular disease. Curr Opin Lipidol 15 (2004) 269-278
35. Nicholls S.J., Zheng L., and Hazen S.L. Formation of dysfunctional high-density lipoprotein by myeloperoxidase. Trends Cardiovasc Med 15 (2005) 212-219
36. Navab M., Anantharamaiah G.M., Reddy S.T., Hama S., Hough G., Grijalva V.R., Wagner A.C., Frank J.S., Datta G., Garber D., and Fogelman A.M. Oral D-4F causes formation of pre-β high-density lipoprotein and improves high-density lipoprotein-mediated cholesterol efflux and reverse cholesterol transport from macrophages in apolipoprotein E-null mice. Circulation 109 (2004) 3215-3220